Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045564 | 0.85 | GRIN2D (0.31) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL2045566 | 0.85 | GRIN2D (0.31) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL6194463 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL11063309 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL5741827 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL6194459 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL8082584 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL7247702 | 0.83 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL7247699 | 0.83 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL6891299 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7242690-A | — | — | None | — | — | JP | disclosed |
| EP-1609785-B1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-1980560-B1 | C-glycoside derivatives for the treatment of diabetes | ASTELLAS PHARMA INC (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1980560-A2 | C-glycoside derivatives for the treatment of diabetes | Astellas Pharma Inc. (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| JP-H07242690-A | PRODUCTION OF ACETALS | SUMITOMO PHARMACEUT CO LTD | 1995-09-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | GRIN2D 3046/4885GRIN3B 2509/4885ADRA1D 2505/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | GRIN2D 3046/4885GRIN3B 2509/4885ADRA1D 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.